Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPM514 in advanced ESCC
NCT07203898Phase 1Not yet recruiting
- Sponsor
- Beijing Immupeutics Medicine Technology Limited
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Therapeutic Vaccines
01
Overview
Phase 1, open-label, single-arm trial of IPM514 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Beijing Immupeutics Medicine Technology Limited. Primary endpoints: Number of Participants with Adverse Events and Pharmacokinetic parameters. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
IPM514
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07203898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07203898.